Sexual Arousal Disorder, Sexual Dysfunction
Conditions
Keywords
Sexual arousal disorder
Brief summary
The aim of this study to determine the effect of clitoral therapy device EROS device/ on sexual dysfunction after genital mutilation.
Detailed description
Little attention has been given to women who exposed to genital mutilation surgery in early age in the middle east. Most of them suffer from sexual dysfunction of sexual arousal and orgasm when they get in an intimate relation with their husbands after marriage. Clitoral therapy device may improve sexual arousal and alleviate sexual dysfunction symptoms to a great extent.
Interventions
DEVICEEROS device
Eros is a small, hand-held device fitted with a removable, replaceable small plastic cup used as a natural way to initiate female sexual response. It was originally cleared by the FDA in April 2000 for the treatment of Female Sexual Arousal Disorder (FSAD), which includes problems with sexual arousal and orgasm.
BEHAVIORALPsychosexual support
Strategies are suggested to improve the couple's emotional connection and communication, when couples are being consulted, they are encouraged to focus on the strengths as well as weaknesses in their relationship. Homework assignments are given for the couple to practice skills, such as turning the idea of sexual obligation into pleasure, learning to focus on sensations rather than anxieties and communicating openly with their partner.
Sponsors
Badr University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
20 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* All are suffering sexual dysfunction of sexual arousal and all referred from the family planning and reproductive health department, National research Center.
Exclusion criteria
* Metastatic disease, severe bowel or bladder sequelae, and significant comorbidities. Women with a history of sexual trauma or abuse, or undergoing current antidepressant therapy were excluded.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The Female Sexual Function Index (FSFI). | Change from baseline sexual function at 3 months. | Female sexual dysfunction has traditionally included disorders of desire. libido, arousal, pain/discomfort, and inhibited orgasm. |
Countries
Egypt
Contacts
Primary ContactHEND SAKR, PhD
Backup ContactMariam El-Ebrashy, PhD
Outcome results
None listed